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1. Introduction 
The proteasome is responsible for the majority of intracellular 
protein turnover in eukaryotic cells, via the ubiquitin-proteasome 
pathway, including the degradation of many critical proteins.1 
Identification of this enzyme complex as an effective therapeutic 
anticancer target has led to the development of numerous 
proteasome inhibitors, which are typically peptide-based and 
contain an electrophilic trap that reacts with the active N-terminal 
threonine of the proteolytic β1, β2 and β5-subunits.2,3 While 
sharing the same catalytic mechanism these subunits differ in 
their substrate preference and cleave near acidic, basic and 
hydrophobic amino acid residues, respectively.4 Although 
achievement of subunit specificity is mainly governed by the 
peptide backbone of the inhibitors, the target specificity and 
biological stability are determined by the electrophilic trap.5 The 
most common electrophilic traps used for covalent proteasome 
inhibition are aldehydes, boronates, vinyl sulfones α’, β’-
epoxyketones and β-lactones. The main focus in the current 
design of proteasome inhibitors is avoiding “off-target” 
interactions and the development of resistance.6 
Presently, a dominant electrophilic trap incorporated in 
proteasome inhibitors is the α,β unsaturated sulfone Michael 
acceptor. In fact, Michael acceptors are nowadays the most often 
used "warheads" in covalent enzyme inhibition, including kinase7 
and cysteine protease8 inhibition. Although vinyl sulfones inhibit 
both the proteasome and cysteine proteases, high selectivity has 
been achieved through manipulation of the peptidic portion.9 
Examples of this are the selective inhibition of the caspase-like 
activity of the proteasome,10 selective labelling of proteasomes,11 
and proteasome subunit specific probes.12 
Adjustment of the chemical environment of the warhead plays a 
key role in inhibitor design since it enables the tuning of its 
reactivity and thereby its selectivity and stability. As a promising 
alternative electrophilic trap, we have described previously the 
incorporation of amino acid derived sulfonyl fluorides13 into 
peptide backbones leading to peptido sulfonyl fluorides (PSF) as 
a new class of powerful proteasome inhibitors, showing a high 
specificity for the β5-subunit.14 Several of these compounds 
could also effectively suppress malaria parasitic activity.15 In 
addition, compounds containing the sulfonyl fluoride electrophile 
have found chemical biology applications as reactive probes, and 
have recently been highlighted as privileged warheads.16 
Structural analysis of the molecular mechanism of action of PSF 
inhibitors in the proteasome revealed the formation of an O-
sulfonate adduct with the active site threonine, which may occur 
by direct nucleophilic substitution of the Fluor-atom or involve 
formation of a sulfene intermediate after proton abstraction 
(Scheme 1).17 We have indications favoring the latter pathway 
from deuterium exchange experiments (unpublished data). 
However, we cannot completely rule out reaction of the SF 
through direct substitution, since (partial) epimerization, 
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indicative of the sulfene mechanism, may already have taken 
place before substitution. 
For a sulfene-like mechanism, it is believed that two factors are 
important for the reactivity of the SF warhead: (1) ease of 
formation of the sulfene intermediate by deprotonation at the α-
position; (2) steric hindrance: a more hindered SF will be less 
accessible for a nucleophile present in the active site of the 
proteasome. The latter factor may also play a role in the direct 
substitution mechanism. 
 
In this research we present attempts towards tuning the reactivity 
of the sulfonyl fluoride (SF) warhead by changing the position of 
the substituent from the β to the α-position that is adjacent to the 
SF-moiety. 
 
Although, alike our present β-substituted SFs, α-substituted SFs 
can still be conveniently derived from α-amino acids (Scheme 2), 
in the synthetic route towards α-substituted SFs further 
manipulation is required in order to shift the side chain to the 
desired α-position. This could be achieved by preparation of 
suitable epoxide derivative from an α-amino acid, followed by 
ring opening to re-introduce the amino functionality at the least 
hindered epoxide-carbon atom (Scheme 2). 
2. Results and Discussion 
\Synthes is  and react ivi ty  o f  α -subst i tu ted  amino 
sul fonyl  f luorides  (SFs)  
Leucine (1a) and Phenylalanine (1b) were converted into the 
corresponding α-bromo acids 2a-b with retention of 
configuration in a diazotisation reaction in the presence of KBr. 
These amino acids were selected because side chains derived 
from Leucine and Phenylalanine are present at the C-terminus of 
several proteasome inhibitors. Esterification led to ethylesters 3a 
and 3b with an optical purity in agreement with the literature.19 
After reduction with in situ prepared LiBH4, bromo-alcohols 4a 
and 4b were obtained in acceptable yields. Next, epoxides 5a and 
5b were prepared with inversion of configuration by treatment 
with base (Cs2CO3),
20  
which were immediately ring-opened by aqueous ammonia,21 
followed by protection of the amine with a Cbz-group22 affording 
7a and 7b in good (over 3 steps) yields of 64 and 80%, 
respectively. Alanine derived Cbz-protected amino alcohol 7c 
was obtained upon protection of the commercially available (R)-
1-amino-2-propanol. Introduction of the thioacetate moiety was 
performed by a Mitsunobu reaction,23 which should take place 
with inversion and thereby a net retention of configuration of 
bromo alcohols 4a,4b. Purification of the resulting thioacetates 
8a-8c turned out to be difficult and reduced the yields 
considerably. Oxidation using aqueous hydrogen peroxide (30% 
w/w) and acetic acid afforded sulfonates 9a-c, after which the 
desired α-substituted sulfonyl fluorides 10a-c were obtained in 
modest yields (24-29%)a.  
At this stage we wished to obtain a general idea of the reactivity 
of α-substituted SF warhead containing compounds with respect 
to nucleophiles and whether this behavior was different from our 
earlier β-substituted SF warhead containing compounds.  
For this α-substituted SFs 10a and 10b were compared with β-
substituted SF 11 (Figure 1, Table 1). It was found that α-
substituted SFs did not differ from the β-substituted SFs with 
respect to their reactivity toward different nucleophiles.b Both 
categories of SFs do not react with thiols, even not in the 
presence of base (DiPEA). In fact, the relatively low reactivity of 
the sulfonyl fluoride group has been synthetically exploited for 
selective modifications in molecules containing other 
electrophilic moieties.24 
In addition, both SFs do react with amine nucleophiles such as 
piperidine and benzylamine. However, α-substituted SFs gave 
rise to more sulfonamide product formation after 24h, possibly 
indicative of a higher reactivity of α-substituted SFs (Table 1). 
This cannot be attributed to formation of a sulfene intermediate 
since abstraction of the α-proton in 10a is probably more difficult 
——— 
a The low yields are probably partly due to impurities present in the 
sulfonate salts, which are difficult to remove by chromatographic 
approaches.  
b The results for the reactivity of these substituted fluorides are in 
agreement with our earlier observed reactivity with unsubstituted 
sulfonyl fluorides.24 
Scheme 1 Proteasome inhibition by a β-substituted SF and proposed 
inhibition by an α-substituted SF. Although indicated as "direct 
substitution" the mechanism probably involves a trigonal bipyramidal 
intermediate.18 
Scheme 2 General synthesis of β-substituted SFs and α-substituted SFs 
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a trigonal bipyramidal intermediate in the "direct substitution"c 
 
 
Incorporat ion  o f  α -subst i tu ted  SFs towards  
potent ia l  proteasome inhib i tors  
To evaluate the inhibitory potential of α-substituted SFs they 
were incorporated into peptide sequences derived from our 
earlier peptido sulfonyl fluoride (PSF) proteasome inhibitors 12, 
13 and 14. We showed that these PSFs were very powerful 
proteasome inhibitors14,17 and therefore their structural 
characteristics are suitable for further structure-activity studies.  
 
Figure 1 Earlier developed PSF-proteasome inhibitors 12-14 containing 
a β-substituted SF derivative. 
 
Cbz-Leu2OH 17 and Cbz-Leu3OH 20 were synthesized in 
solution in a few steps starting from methyl ester 15 as was 
described previously28. Carboxylic acids 17 and 20 were obtained 
(95% yield) after saponification of methyl esters 16 and 19 with 
Tesser’s base (dioxane/methanol/4N NaOH 4:5:1) (Scheme 3).  
Morpholino-hPhe-Leu-Phe-OH 23 was prepared by solid phase 
synthesis starting from chloro-trityl resin 21 using Fmoc-
chemistry and cleavage from the resin using hexafluoro-iso 
propanol (HFIP).  
 
Completion of the inhibitor synthesis was achieved by first 
deprotecting SFs 10a,b by HBr in acetic acid and ion-exchange 
to the HCl-salt, followed by a DCC-coupling in the presence of  
——— 
c a trigonal bipyramidal intermediate (TBPI) may offer relieve of 
strain going from ca. 109o angles in starting material to ca 120o in the 
TBPI mechanism (Scheme 1) allowing "steric acceleration".25 
 
6-chloro-HOBt (HOBt-Cl). (Scheme 4) Liberation of the 
hydrochloride salt using Zn powder in THF26 and the 
DCC/HOBt-Cl coupling method provided essentially neutral 
conditions to prevent further decomposition of the SF-warhead  
 
and minimize possible racemization of the warhead. 
PSF-inhibitors 25a,b - 27a,b were obtained after preparative 
reverse phase HPLC purification as diasteroisomeric mixtures in 
rather low yields (10-21%). The diastereomeric ratios were 
identical to those observed after the introduction of the SF under 
more basic coupling conditions during control experiments. 
Therefore, it was concluded that racemisation had occurred 
during the synthesis of the warhead, possibly after introduction of 
the sulfonyl moiety, which increases the acidity of the α-proton 
significantly. All attempts to separate the diastereomers by 
reverse phase HPLC failed.  
 
Hydrolytic stability and biological activity 
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Scheme 3  Synthesis in solution of Cbz-Leu2OH 17 and Cbz-Leu3OH 20 
and Solid phase synthesis of Morph-hPhe-Leu-Phe-OH 23. 
The behavior of α-PSFs 25a, 26a and the β-PSF inhibitors 12 
and 13 in an aqueous buffer at different pHs was studied (Figure 
3). Although all tested PSFs showed a considerable aqueous 
stability, the α-PSFs 25a, 26a appeared to be more prone to 
undergo hydrolysis than their β-PSF counterparts 12 and 13. 
Surprisingly, hydrolysis of 25a at acidic pH was initially fast 
and then remained unchanged. The half-life of α-PSFs 25a and 
26a at the different pH's varied between ca. 5-7 hours, whereas 
the β-PSF inhibitors 12 and 13 were more stable, and depending 
on the pH their half-life varied between ca 10-12 hours. 
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It was attempted to determine inhibition of the proteasome 
enzymatic activity by monitoring inhibition of the hydrolysis of 
the fluorogenic substrate Suc-LLVY-AMC27 Unexpectedly, our 
inhibitors showed no proteasome inhibition in the used 
concentration range from 0.002 μM - 400 μM. However, 
strangely, it was impossible to obtain the normal sigmoid 
inhibition curves for any of the α-PSFs 25-27ab, where it was 
possible to produce in the same assay sigmoid inhibition curves 
for β-PSF inhibitors 12 and 13. (see supporting information, page 
S116). Possible explanations for this anomalous behavior include 
a complete devoid of activity of the compounds in the above used 
concentration range. However, this concentration range may not 
have been actually realized, since at a concentration of ca. 75 
μM, compounds were starting to precipitate from the solution. 
With respect to this it is also noteworthy that at low 
concentrations (between ca. 0.1 - 1 μM, see supporting 
information, page S112 ) of a few inhibitors a start of a sigmoidal 
curve could be discerned, possibly indicating that a these 
concentrations the inhibitors are still soluble and capable of 
proteasome inhibition.  
Increasing the DMSO concentration to 20% v/v (this is the 
maximal concentration tolerated by the proteasome) did not 
remedy this situation. Unfortunately, at this point we are unable 
to draw definitive conclusions about the proteasome inhibitory 
activity of the α-PSFs 25-27ab as compared to the β-PSF 
inhibitors 12 and 13. 
 
3. Conclusions  
 
Several new amino acid derived SFs have been synthesised 
containing the substituent in the α-position with respect to the 
SF moiety. The preparation of these αSFs was achieved using α-
amino acids as starting materials leading to epoxides as synthons 
for shifting the side chain to the α-position with respect to the 
SF-moiety. An important future issue might be exact 
determination of the racemization causes and in which stage 
separation of the diastereoisomers should take place. 
Although αSFs seemed to be slightly more reactive than a βSFs it 
is not clear as yet if and how this is translated to the bio-activity 
of the corresponding α-PSFs probably because of very poor 
solubility of α-PSFs 25-27ab. Evidently, our near future research 
efforts will involve trying to improve the solubility of α-PSFs for 
example by modifying or removing the N-terminal protecting 
group. 
 
4. Experimental part 
All reagents were obtained from commercial sources and used 
without further purification unless specified otherwise. Air and/or 
moisture sensitive reactions were performed under an atmosphere 
of nitrogen in flame dried apparatus. Tetrahydrofuran (THF) and 
dichloromethane (CH2Cl2) were purified using a Pure-Solv
TM 500 
Solvent Purification System. Petroleum ether (PE) used for 
reactions and column chromatography was the 40–60 °C fraction. 
Thin layer chromatography (TLC) was performed using Merck 
silica gel 60 glass plates F254. TLC plates were visualized under 
UV light at λ = 254 nm and stained using the most appropriated 
solution (ninhydrin, anisaldehyde, bromocresol green or 
Scheme 4 Incorporation of the α-substituted SFs to yield proteasome 
inhibitors 25a,b, 26a,b and 27a,b. 
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Figure 3 Buffer stability studies of compounds 25a, 26a, 12 and 13 
at pH 6.5, 7.4 and 8.0 
potassium permanganate). Flash column chromatography was 
performed with Silicaflash P60 gel (40–63 μm) from Silicycle 
(Canada) as solid support. All 1H NMR spectra were recorded on 
Bruker Avance III 400 MHz and 500 MHz spectrometers at 
ambient temperature. Data are reported as follows: chemical 
shifts in ppm relative to TMS (0.0) on the δ scale, multiplicity (s 
= singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = 
broad, app. = apparent or a combination of these), coupling 
constant(s) in J (Hz), integration and assignment. All 13C NMR 
spectra were recorded on Bruker Avance III 400 MHz and 500 
MHz spectrometers at 101 MHz and 126 MHz at ambient 
temperature and assignments were carried out and/or confirmed 
using 2D spectra (HSQC, COSY) and DEPT. Data are reported 
as follows: chemical shift in ppm relative to CDCl3 (77.0) on the 
δ scale and assignment. All 19F NMR spectra were recorded on 
Bruker Avance III 500 MHz spectrometer at 471 MHz at ambient 
temperature. Chemical shifts are reported in ppm. Optical 
rotations were recorded using an automatic polarimeter Autopol 
V. High resolution mass spectra (HRMS) were recorded using 
positive chemical ionization (CI+) and electron impact (EI+) on 
Jeol MStation JMS-700 instrument and positive or negative ion 
electrospray (ESI+/ESI-) techniques on a Bruker micrOTOF-Q 
instrument. Analytical HPLC was performed on a Shimadzu 
Prominence instrument with a UV-detector operating at λ = 214 
and 254 nm, using a C4 column (5 µm, 250 x 4.60 mm) or a C18 
column (5 µm, 250 x 4.60 mm) at a flow rate of 1 mL/min. The 
mobile phase was water/CH3CN/TFA (95/5/0.1, v/v/v, buffer A) 
and water/CH3CN/TFA (5/95/0.1, v/v/v, buffer B). Samples were 
dissolved in buffer A/B (1/2 or 1/3). Preparative HPLC was 
performed on an Agilent 1260 Infinity instrument using a 
Phenomenex column (Gemini C18, 10 µm, 250 x 21.2 mm) at a 
flow rate of 12.5 mL/min, using the same buffers and sample 
preparation as described for the analytical HLPC. Analytical LC-
MS was performed on a Thermo Scientific Dionex Ultimate 3000 
LC system coupled to a Thermo Scientific LCQ FleetTM Ion trap 
mass spectrometer using a Dr. Maisch column (Reprosil Gold 
120, C18, 3 µm, 150 x 4mm) with a linear gradient of 1 mL/min. 
The mobile phase was water/CH3CN/TFA (95/5/0.1, v/v/v, buffer 
A) and water/CH3CN/TFA (5/95/0.1, v/v/v, buffer B). Samples 
were dissolved in buffer A/B (1/1 or 1/2). The UV absorption 
was monitored at λ = 214 and 254 nm over 10, 40 or 60 min. 
Proteasome Enzymatic Assays were performed using the Enzo 
Life Sciences® 20S Proteasome Assay Kit for Drug Discovery 
(Enzo Life Science, USA). Fluorescence measurements were 
performed with a Clariostar microplate reader (BMG LABTECH, 
Germany). Diastereomeric ratios of the final inhibitors were 
determined from integration values of separated signals in 1H 
NMR spectra. 
Cbz-sulfonate salt 9a 
Thioacetate 8a (1.6 g, 4.7 mmol) was dissolved in acetic acid (15 
mL) and an aqueous 30% H2O2  solution (5 mL) was added. The 
reaction was stirred at RT overnight. NaOAc (425 mg, 5.2 mmol) 
was added and the mixture was stirred at RT for 1 h. Acetic acid 
was then removed in vacuo and DMF was added (50 mL). Co-
evaporation with DMF was repeated using the same amount until 
the excess of hydrogen peroxide/peracetic acid was removed 
(checked with a starch iodide paper). The crude mixture was then 
diluted with more water and lyophilised resulting in the desired 
sulfonate salt. The crude sulfonate was used as such in the 
fluorination step. 
HRMS (ESI positive) calcd for C14H20NNaO5S [M+Na]
+ 
360.0852, found 360.0843. 
Cbz-sulfonate salt 9b 
Thioacetate 8b (4.2 g, 13.6 mmol) was dissolved in acetic acid 
(50 mL) and an aqueous 30% H2O2  solution (18 mL) was added. 
The reaction was stirred at RT overnight. NaOAc (1.2 g, 15 
mmol) was added and the mixture was stirred at RT for 1 h. 
Work-up was carried out as was described for 9a. 
HRMS (ESI positive) calcd for C7H18NNaO5S [M+Na]
+ 
394.0696, found 394.0693. 
Cbz-sulfonate salt 9c 
Thioacetate 8c (2.16 g, 8.1 mmol) was dissolved in acetic acid 
(25 mL) and an aqueous 30% H2O2 solution (9 mL) was added. 
The reaction was stirred at RT overnight. NaOAc (730 mg, 8.9 
mmol) was added and the mixture was stirred at RT for 1 h. 
Work-up was carried out as was described for 9a. 
HRMS (ESI negative) calcd for C11H14NO5S [M-H]
- 272.0598, 
found 272.0578. 
Cbz-sulfonyl fluoride 10a 
 
The crude sulfonate salt 9a (300 mg, 0.94 mmol) was dissolved 
in dry DCE (45 mL). XtalFluor-M (353 mg, 1.45 mmol) and 
NEt3·3HF (6 μL, 0.03 mmol) were added and the reaction was 
stirred under nitrogen atmosphere at reflux overnight. 
Evaporation of the solvent in vacuo and purification of the crude 
product by silica gel column chromatography (EtOAc/n-hex, 
0/102/8, v/v) afforded the desired sulfonyl fluoride (60 mg, 
0.19 mmol, 24%) as a colourless oil. 
1H NMR (500 MHz, CDCl3) δ 7.33 – 7.15 (m, 5H, CH-Ph), 5.26 
(br s, 1H, NH), 5.03 (m, 2H, CH2-C4), 3.74 – 3.65 (ddd, J = 12.4, 
6.9, 2.2 Hz, 1H, CH2-C2a), 3.50 (m, 2H, CH2-C2b, CH-C1), 1.86 
– 1.77 (m, 1H, CH-C7), 1.73 (m, 1H, CH2-C6a), 1.59 – 1.50 
(ddd, J = 14.2, 8.8, 5.4 Hz, 1H, CH2-C6b), 0.89 (d, J = 6.5 Hz, 
3H, CH3-C8), 0.88 (d, J = 6.5 Hz, 3H, CH3-C9). 
13C NMR (126 MHz, CDCl3) δ 156.4 (C-C3), 136.1 (C-C5), 
128.7 (CH-Ph), 128.4 (CH-Ph), 128.2 (CH-Ph), 67.3 (CH2-C4), 
61.6 (d, J = 9.4 Hz, CH-C1), 40.1 (CH2-C2), 35.6 (CH-C6), 25.3 
(CH-C7), 22.8 (CH3-C8), 21.5 (CH3-C9). 
19F NMR (471 MHz, CDCl3) δ 48.38. 
HRMS (ESI positive) calcd for C14H20FNO4S [M+H]
+ 317.1097, 
found 317.1101. 
Cbz-sulfonyl fluoride 10b 
 
The crude sulfonate salt 9b (300 mg, 0.85 mmol) was dissolved 
in dry DCE (45 mL). XtalFluor-M (353 mg, 1.45 mmol) and 
NEt3·3HF (6 μL, 0.03 mmol) were added and the reaction was 
stirred under nitrogen atmosphere at reflux overnight. 
Evaporation of the solvent in vacuo and purification of the crude 
product by silica gel column chromatography (EtOAc/n-hex, 
0/102/8, v/v) afforded the desired sulfonyl fluoride (70 mg, 
0.20 mmol, 25%) as white crystals. 
1H NMR (500 MHz, CDCl3) δ 7.38 – 7.06 (m, 10H, CH-Ph), 
5.17 (br s, 1H, NH), 5.06 – 4.94 (m, 2H, CH2-C4), 3.81 (m, 1H, 
CH-C1), 3.65 (ddd, J = 14.7, 6.2, 3.0 Hz, 1H, CH2-C2a), 3.52 
(app dt, J = 14.7, 6.9 Hz, 1H, CH2-C2b), 3.34 (dd, J = 14.4, 4.6 
Hz, 1H, CH2-C6a), 2.93 (dd, J = 14.4, 9.5 Hz, 1H, CH2-C6b). 
 13C NMR (126 MHz, CDCl3) δ 156.0 (C-C3), 135.9, 134.5 (C-
C5, C7), 129.1 (CH-Ph), 129.0 (CH-Ph), 128.6 (CH-Ph), 128.3 
(CH-Ph), 128.1 (CH-Ph), 127.8 (CH-Ph), 67.2 (CH2-C4), 63.9 (d, 
J = 8.8 Hz, CH-C1), 39.5 (CH2-C2), 33.1 (CH2-C6). 
19F NMR (471 MHz, CDCl3) δ 50.56. 
HRMS (ESI positive) calcd for C17H18FNNaO4S [M+Na]
+ 
374.0833, found 374.0828. 
Cbz-sulfonyl fluoride 10c 
 
The crude sulfonate salt 9c (1.4 g, 5 mmol) was dissolved in dry 
DCE (200 mL). XtalFluor-M (2.1 g, 8.5 mmol) and NEt3·3HF 
(59 μL, 0.4 mmol) were added and the reaction was stirred under 
nitrogen atmosphere at reflux overnight. Evaporation of the 
solvent in vacuo and purification of the crude product by silica 
column chromatography (EtOAc/n-hex, 4/6, v/v) afforded the 
desired sulfonyl fluoride (230 mg, 0.89 mmol, 29%) as a yellow 
oil. 
1H NMR (500 MHz, CDCl3) δ 7.37 – 7.16 (m, 5H, CH-Ph), 5.30 
– 5.18 (br s, 1H, NH), 5.11 – 5.00 (m, 2H, CH2-C4), 3.72 – 3.55 
(m, 3H, CH-C1, CH2-C2), 1.47 (d, J = 6.9 Hz, 3H, CH3-C6). 
13C NMR (126 MHz, CDCl3) δ 156.4 (C-C3), 136.0 (C-C5), 
128.7 (CH-Ph), 128.5 (CH-Ph), 128.2 (CH-Ph), 67.4 (CH2-C4), 
58.3 (d, J = 11.7 Hz, CH-C1), 41.6 (CH2-C2), 12.8 (CH3-C6). 
19F NMR (471 MHz, CDCl3) δ 46.10. 
HRMS (ESI positive) calcd for C11H14FNNaO4S [M+Na]
+ 
298.0520, found 298.0506. 
General procedure for the coupling of α-substituted amino 
sulfonyl fluorides 
Cbz-protected sulfonyl fluoride 10a,b or c was treated with a 1:1 
mixture of HBr/HOAc solution : CH2Cl2 for 1 h. After 
evaporation of the solvents, the crude product was dissolved in 
H2O, stirred with Dowex-Cl resin (60 mg/0.1 mmol crude 
product) for 10 min, filtered and freeze dried, resulting in the 
corresponding hydrochloride salt. To generate the free amine in 
situ the salt was dissolved in THF (1mL/0.1 mmol) and treated 
with Zn powder (2 eq) for 30 min. After filtration, the amine was 
added to the reaction mixture of the peptide backbone (1 eq), 
DCC (1.1 eq) and HOBt-Cl (1.1 eq) in THF (1mL/0.1 mmol), 
which had been previously pre-activated for 10 min. The reaction 
was then stirred overnight. After concentration by evaporation of 
the volatiles, the crude product was dissolved in a 1:3 mixture of 
buffer A and buffer B and purified by preparative HPLC 
affording the desired compound. 
 
Cbz-Leu-Leu-Leu-SO2F 25a 
 
The general procedure was followed on a 0.157 mmol scale 
delivering the desired product (15 mg, 0.027 mmol, 18%) as a 
white solid. Diastereomeric ratio 2.5:1, NMR-shifts of the 
diastereomer are indicated by a '*' 
1H NMR (400 MHz, Chloroform-d) δ 7.40 – 7.30 (m, 7H, CH-
Ph, CH-Ph*), 7.13 (s, 1H, NH), 6.95 (s, 0.4H, NH*), 6.47 (d, J = 
8.0 Hz, 0.4H, NH*), 6.41 (d, J = 8.0 Hz, 1H, NH), 5.18 – 5.08 
(m, 4.2H, NH, NH*, CH2-C8, CH2-C8*), 4.50 – 4.35 (m, 1.4H, 
CH-C4, CH-C4*), 4.18 – 4.09 (m, 1.4H, CH-C6, CH-C6*), 3.83 
– 3.69 (m, 2.4H, CH2-C2a, CH2-C2a*, CH-C1), 3.65 – 3.48 (m, 
1.8H, CH2-C2b, CH2-C2b*, CH-C1*), 1.97 – 1.43 (m, 12.6H, 
CH2-C9, C13, C17, CH-C10 C14, C18, CH2-C9*, C13*, C17*, 
CH-C10*, C14*, C18*), 1.05 – 0.84 (m, 25.2H, CH3-C11, C12, 
C15, C16, C19, C20, CH3-C11*, C12*, C15*, C16*, C19*, 
C20*). 
13C NMR (101 MHz, CDCl3) δ 172.6, 172.4, 172.3 (C-C5, C3, 
C-C5*, C3*), 156.8 (C-C7, C-C7*), 135.9 (C-Ph*), 135.8 (C-
Ph), 128.6, 128.4, 128.3, 128.2, 128.1 (CH-Ph, CH-Ph*)), 67.6 
(CH2-C8), 67.4 (CH2-C8*), 61.0 (d, J = 9.4 Hz, CH-C1*), 60.5 
(d, J = 9.7 Hz, CH-C1) 54.2 (CH-6), 53.9 (CH-C6*), 52.0 (CH-
C4*), 51.7 (CH-C4), 40.7, 40.2, 40.1 (CH2-C9, C13, CH2-C9*, 
C13*), 38.7 (CH2-C2, C2*), 35.9(CH2-C17, CH2-C17*), 25.3, 
24.9, 24.8, 24.7 (CH-C10, C14, C18, CH-C10*, C14*, C18*), 
22.9, 22.7, 21.7, 21.6, 21.5, 21.4 (CH3-C11, C12, C15, C16, C19, 
C20). 
19F NMR (377 MHz, CDCl3) δ 48.8, 48.4. 
HRMS (ESI positive) calcd for C26H42FN3NaO6S [M+Na]
+ 
566.2671, found 566.2647. 
tR = 53.8 min (Gemini column C18, 10 µm, 250 x 21.2 mm, 0B 
to 100B in 80 min) 
 
Cbz-Leu-Leu-Phe-SO2F 25b 
 
The general procedure was followed on a 0.14 mmol scale 
delivering the desired product (10 mg, 0.017 mmol, 12%) as a 
white solid. Diastereomeric ratio 5:1,NMR-shifts of the 
diastereomer are indicated by a '*'. 
1H NMR (500 MHz, CDCl3) δ 7.35 – 7.22 (m, 12.2H, CH-Ph, 
CH-Ph*, NH*), 7.08 – 7.00 (br s, 1H, NH), 6.80 (br s, 0.2H, 
NH*), 6.30 (d, J = 8.0 Hz, 1.2H, NH, NH*), 5.17 – 5.09 (m, 
2.4H, CH2-C8, CH2-C8*), 5.08 – 5.03 (br s, 1H, NH), 4.36 (m, 
1.2H,CH-C4, CH-C4*), 4.09 (m, 2H, CH-C6, CH-C1), 3.91 (m, 
0.4H, CH-C6*, C1*), 3.73 (m, 1.2H, CH2-C2a, CH2-C2a*), 3.56 
(app dt, J = 14.6, 7.0 Hz, 1.2H, CH2-C2b, CH2-C2b*), 3.39 (dd, J 
= 14.5, 4.9 Hz, 1.2H, CH2-C17a, CH2-C17a*), 2.99 (dd, J = 14.5, 
9.3 Hz, 1.2H, CH2-C17b, CH2-C17b*), 1.79 – 1.42 (m, 7.2H, 
CH2-C9, C13, CH-C10, C14, CH2-C9*, C13*, CH-C10*, C14*), 
0.97 – 0.85 (m, 14.4H, CH3-C11, C12, C15, C16, CH3-C11*, 
C12*, C15*, C16*). 
13C NMR (101 MHz, CDCl3) δ 172.5, 172.2 (C-C4, C6, C-C4*, 
C6*), 156.8 (C-C7, C-C7*), 135.8, 135.7 , 134.6 (C-Ph, C-Ph*), 
129.1, 129.0, 128.6, 128.4, 128.2, 128.1, 127.7 (CH-Ph, CH-
Ph*), 67.6 (CH2-C8), 67.4 (CH2-C8*), 63.4 (CH-C1*), 62.8 (d, J 
= 8.6 Hz, CH-C1), 54.2 (CH-C6, CH-C6*), 51.9 (CH-C4*), 51.7 
(CH-C4), 40.6, 40.2, 40.0 (CH2-C9, C13, CH2-C9*, C13*), 38.2 
(CH2-C2), 37.9 (CH2-C2*), 33.4 (CH2-C17, CH2-C17*), 24.9, 
24.8, 24.7 (CH-C10, C14, CH-C10*, C14*), 22.9, 21.7, 21.5 
(CH3-C11, C12, C15, C16, CH3-C11*, C12*, C15*, C16*). 
19F NMR (377 MHz, CDCl3) δ 51.31, 50.76. 
HRMS (ESI positive) calcd for C29H40FN3NaO6S [M+Na]
+ 
600.2514, found 600.2492 
tR = 44.0 min (Gemini column C18, 10 µm, 250 x 21.2 mm, 10B 
to 100B in 80 min) 
 
Cbz-Leu-Leu-Leu-Leu-SO2F 26a 
 
The general procedure was followed on a 0.17 mmol scale 
delivering the desired product (15 mg, 0.023 mmol, 14%) as a 
white solid. Diastereomeric ratio 5:1, NMR-shifts of the 
diastereomer are indicated by a '*'. 
1H NMR (500 MHz, CDCl3) δ 7.43 – 7.28 (m, 7.2H, CH-Ph, 
NH, CH-Ph*, NH*), 7.17 (br s, 0.2H, NH*), 6.95 (d, J = 7.7 Hz, 
1.2H, NH, NH*), 6.46 (br s, 1H, NH), 5.21 – 5.05 (m, 3.6H, NH, 
CH2-C10, NH*, CH2-C10*), 4.45 – 4.37 (m, 1.2H, CH-C6, CH-
C6*), 4.29 – 4.22 (m, 1.2H, CH-C4, CH-C4*), 4.12 (app dt, J = 
17.0, 8.5 Hz, 1.2H, CH-C8, CH-C8*), 3.82-3.71 (m, 2.4H, CH2-
C2a, CH-C1, CH2-C2a*, CH-C1*), 3.69-3.63 (m, 0.2H, CH2-C2b 
*), 3.58 – 3.49 (m, 1H, CH2-C2b), 1.98 – 1.44 (m, 14.4H, CH2-
C11, C15, C19, C23, CH-C12, C16, C20, C24, CH2-C11, C15, 
C19, C23, CH-C12*, C16*, C20*, C24*), 1.03 – 0.81 (m, 28.8H, 
CH3-C13, C14, C17, C18, C21, C22, C25, C26, CH3-C13*, 
C14*, C17*, C18*, C21*, C22*, C25*, C26*). 
13C NMR (126 MHz, CDCl3) δ 173.4, 173.1, 171.8 (C-C7, C5, 
C3, C-C7*, C5*, C3*), 156.9 (C-C9, C-C9*) , 135.6 (C-Ph, C-
Ph*), 128.7, 128.6, 128.0 (CH-Ph, CH-Ph*), 67.6 (CH2-C10, 
CH2-C10*), 60.2 (d, J = 8.1 Hz, CH-C1), 54.7 (CH-C8, CH-
C8*), 53.4 (CH-C4, CH-C4*), 52.1, 51.9 (CH-C6, CH-C6*), 
40.6, 39.9, 39.8, (CH2-C11, C15, C19, CH2-C11*, C15*, C19*), 
39.1 (CH2-C2, CH2-C2*), 36.1 (CH2-C23, CH2-C23*), 25.4, 
25.3, 25.01, 24.9, 24.8 (CH-C12, C16, C20, C24, CH-C12*, 
C16*, C20*, C24*), 23.2, 23.0, 22.9, 22.6, 21.6, 21.5, 21.1 (CH3-
C13, C14, C17, C18, C21, C22, C25, C26, CH3-C13*, C14*, 
C17*, C18*, C21*, C22*, C25*, C26*). 
19F NMR (471 MHz, CDCl3) δ 49.75, 48.68. 
HRMS (ESI positive) calcd for C32H53FN4NaO7S [M+Na]
+ 
679.3511, found 679.3474. 
tR = 26.3 min (Gemini column C18, 10 µm, 250 x 21.2 mm, 30B 
to 100B in 80 min) 
 
Cbz-Leu-Leu-Leu-Phe-SO2F 26b 
 
The general procedure was followed on a 0.19 mmol scale 
delivering the desired product (13 mg, 0.019 mmol, 10%) as a 
white solid. Diastereomeric ratio: 3.3:1, NMR-shifts of the 
diastereomer are indicated by a '*'. 
1H NMR (500 MHz, CDCl3) δ 7.38 – 7.16 (m, 14.3H, CH-Ph, 
NH, CH-Ph*, NH*), 7.03 (br s, 1.3H, NH, NH*), 6.54 (br s, 
1.6H, NH, NH*, NH*), 5.19 (d, J = 7.4 Hz, 1H, NH), 5.17-5.10 
(s, 2.6H, CH2-C10, CH2-C10*), 4.46-4.35 (m, 1.3H, CH-C6, CH-
C6*), 4.30-4.23 (m, 1.3H, CH-C4, CH-C4*), 4.17-4.12 (m, 1.3H, 
CH-C8, CH-C8*), 4.12-4.07 (m, 1H, CH-C1), 4.05-3.99 (m, 
0.3H, CH-C1*), 3.74-3.67 (m, 1.3H, CH2-C2a, CH2-C2a*), 3.63 
– 3.53 (m, 1.3H, CH2-C2b, CH2-C2b*), 3.35 (dd, J = 14.5, 5.3 
Hz, 1.3H, CH2-C23a, CH2-C23a*), 3.06 (dd, J = 14.5, 8.3 Hz, 
1H, CH2-C23b), 2.99 (m, 0.3H, CH2-C23b*), 1.92 – 1.39 (m, 
11.7H, CH2-C11, C15, C19, CH-C12, C16, C20, CH2-C11*, 
C15*, C19*, CH-C12*, C16*, C20*), 0.95 – 0.83 (m, 23.4H, 
CH3-C13, C14, C17, C18, C21, C22, CH3-C13*, C14*, C17*, 
C18*, C21*, C22*). 
13C NMR (126 MHz, CDCl3) δ 173.4, 173.1, 171.9 (C-C7, C5, 
C3, C-C7*, C5*, C3*), 156.8 (C-C9, C-C9*), 135.6, 134.9 (C-
Ph, C-Ph*), 129.2, 128.9, 128.7, 128.6, 128.0, 127.5 (CH-Ph, 
CH-Ph*), 67.5 (CH2-C10, CH2-C10*), 62.7 (d, J = 7.7 Hz, CH-
C1), 54.6 (CH-C8, CH-C8*), 53.0 (CH-C4, CH-C4*), 52.0 (CH-
C6, CH-C6*), 40.8, 40.0, 39.8 (CH2-C11, C15, C19, CH2-C11*, 
C15*, C19*), 38.6 (CH2-C2, CH2-C2*), 33.4 (CH2-C23, CH2-
C23*), 25.0, 24.9, 24.8 (CH-C12, C16, C20, CH-C12*, C16*, 
C20*), 23.2, 22.9, 22.8, 21.8, 21.6, 21.2 (CH3-C13, C14, C17, 
C18, C21, C22, CH3-C13*, C14*, C17*, C18*, C21*, C22*). 
19F NMR (471 MHz, CDCl3) δ 52.54, 51.60. 
HRMS (ESI positive) calcd for C35H51FN4NaO7S [M+Na]
+ 
713.3355, found 713.3322. 
tR = 27.8 min (Gemini column C18, 10 µm, 250 x 21.2 mm, 30B 
to 100B in 80 min) 
 
Morph-hPhe-Leu-Phe-Leu-SO2F 27a 
 
The general procedure was followed on a 0.13 mmol scale 
delivering the desired product (20 mg, 0.027 mmol, 21%) as a 
white solid. 
1H NMR (600 MHz, CDCl3) δ 8.69 (br s, 3H, NH), 7.36 – 6.89 
(m, 10H, CH-Ph), 4.78 (m, 3H, CH- C4, C6, C8), 3.93 – 3.45 (m, 
9H, CH2-C13, C14, CH2-C10, CH2-C2, CH-C1), 3.28 – 2.89 (m, 
6H, CH2-C11, C12, CH2-C21), 2.55 (s, 2H, CH2-C16), 2.17 – 
1.71 (m, 5H, CH2-C15, CH2-C22, CH-C23), 1.57 (m, 3H, CH2-
C17, CH-C18), 1.01 – 0.89 (m, 6H, CH3-C24, C25), 0.82 (dd, J = 
19.9, 5.6 Hz, 6H, CH3-C19, C20). 
13C NMR (151 MHz, CDCl3) δ 172.7, 172.1, 171.7, 165.3 (C-C3, 
C5, C7, C9) , 140.6, 136.6 (C-Ph), 129.3, 128.8, 128.6, 128.5, 
128.3, 127.1, 126.5 (CH-Ph), 64.0 (CH2-C13, C14), 61.0 (d, J = 
8.1 Hz, CH-C1), 58.2 (CH2-C10), 54.6, 53.7 (CH-C4, C6), 53.6 
(CH2-C11, C12), 52.3 (CH-C8), 41.7(CH2-C17) , 38.9 (CH2-C2), 
38.1 (CH2-C21), 36.3 (CH2-C22), 33.4 (CH2-C15), 32.2 (CH2-
C16), 25.5, 25.0, (CH-C18, C23), 22.8, 22.6, 22.4, 21.6 (CH3-
C19, C20, C24, C25). 
19F NMR (471 MHz, CDCl3) δ 49.75 
HRMS (ESI positive) calcd for C37H55FN5O7S [M+H]
+ 732.3801, 
found 732.3765.  
tR = 26.8 min (Gemini column C18, 10 µm, 250 x 21.2 mm, 30B 
to 100B in 80 min) 
 
Morph-hPhe-Leu-Phe-Phe-SO2F 27b 
 
The general procedure was followed on a 0.12 mmol scale 
delivering the desired product (10 mg, 0.013 mmol, 11%) as a 
white solid. 
1H NMR (600 MHz, CDCl3) δ 7.37 – 6.99 (m, 15H, CH-Ph), 
4.66 (br s, 2H, CH-C8,) 4.42 (br s, 1H, CH-C4), 3.98 (br s, 1H, 
CH-C1), 3.83 (m, 8H, CH2-C13, C14, CH2-C10, CH2-C2) 3.33 – 
2.87 (m, 8H, CH2-C22, CH2-C11, C12, CH2-C21), 2.65 – 2.59 
(m, 2H, CH2-C16), 2.05 (dd, J = 13.2, 6.3 Hz, 1H, CH2-C15b), 
1.96 (p, J = 7.5, 7.0 Hz, 1H, CH2-C15b), 1.48 (br s, 3H, CH2-
C17, CH-C18), 0.83 (d, J = 5.0 Hz, 3H, CH3-C19/C20), 0.79 (d, 
J = 5.0 Hz, 3H, CH3-C19/C20). 
13C NMR (151 MHz, CDCl3) δ 173.0, 172.8, 172.1, 172.0 (C-C3, 
C5, C7, C9), 140.5, 136.7, 136.6, 134.8 (C-Ph), 129.42, 129.3, 
129.2, 129.2, 129.1, 128.8, 128.7, 128.5, 128.4, 127.9, 127.1, 
126.5 (CH-Ph), 64.6, 64.4(CH2-C13, C14), 63.1 (d, J = 8.2 Hz, 
CH-C1), 59.0 (CH2-C10), 54.5, 53.8 (CH-C4, C6), 53.2 (CH2-
C11, C12), 52.9 (CH-C8), 40.8 (CH2-C17), 38.4 (CH2-C2), 37.4 
(CH2-C21), 33.70 (CH2-C22), 33.4 (CH2-C15), 32.2 (CH2-C16), 
24.9 (CH-C18), 22.7, 21.9 (CH3-C19,C20)  
19F NMR (471 MHz, CDCl3) δ 51.73. 
HRMS (ESI positive) calcd for C40H53FN5O7S [M+H]
+ 766.3644, 
found 766.3608.  
tR = 27.8 min (Gemini column C18, 10 µm, 250 x 21.2 mm, 30B 
to 100B in 80 min) 
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